About

The consultancy born at the intersection of behavioral economics and human experience.

René Studio
AI EXPERIENCE STUDIO

The CX design platform we built from a decade of client work.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Mystery audits we run, scored live for every location.

Explore Mysterya
NOW HIRING

Join a team reshaping how the world experiences brands.

View open roles →

COMPANY

GROW WITH US

CONNECT

Services

Comprehensive CX and management consulting for enterprise brands.

René Studio
AI EXPERIENCE STUDIO

Every engagement, mapped and scored in one AI workspace.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Mystery shopping, scored and evidenced in real time.

Explore Mysterya
ALL SERVICES

Explore the full range of CX & management consulting services.

Browse all services →

CORE

SPECIALIST

Solutions

Structured solutions that turn CX ambition into measurable outcomes.

René Studio
AI EXPERIENCE STUDIO

Map, score and fix the journeys we redesign, with AI.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Check the experience you designed is delivered.

Explore Mysterya
ALL SOLUTIONS

Explore every CX solution we offer.

Browse solutions →

STRATEGY & GOVERNANCE

DESIGN & DELIVERY

CULTURE & EXPERIENCE

Industries

A decade of CX transformation across the region's defining sectors.

René Studio
AI EXPERIENCE STUDIO

Sector-ready journeys, scored by AI in minutes.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Mystery audits tuned to your sector, scored live.

Explore Mysterya
ALL INDUSTRIES

See how we work across every sector.

Browse industries →

BUILT ENVIRONMENT

FINANCE & TECH

PEOPLE & MOBILITY

Products

Proprietary tools, platforms, and AI that power CX transformation.

René Studio
AI EXPERIENCE STUDIO

Design, score and fix customer journeys with AI.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Audit every location and act on what you find.

Explore Mysterya
REBELDECK A · 36 FORCES

The forces that shape how humans experience the world.

Explore REBEL Reveal →
ALL PRODUCTS

Explore the full Renascence product ecosystem.

Browse products →

PLATFORMS

AI & TECHNOLOGY

LEARNING & FRAMEWORKS

CX TOOLKIT

Opinion

Insights, research, and conversations at the frontier of CX.

René Studio
AI EXPERIENCE STUDIO

Turn what you read into a journey you can score.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

See what customers really experience, visit by visit.

Explore Mysterya
ReadExperience JournalArticles & research on CX, behavior, and transformation.Watch & listenExperience LoomOur video podcast on CX & behavior.CuratedCX NewsIndustry news that matters in CX, minus the noise.

Latest articles

Latest episodes

Latest news

Hub

Free tools, templates, and resources to advance your CX practice.

René Studio
AI EXPERIENCE STUDIO

Design, score and fix customer journeys with AI.

Explore René Studio
Mysterya
MYSTERY AUDITS, LIVE

Every visit, every location, every score. Live.

Explore Mysterya
THE MANIFESTOBurn the Deck.
Ten Virtues. Zero Excuses.Start reading →
THE HUB

Every free tool, template and resource in one place.

Visit the Hub →

AI TOOLS

FREE TOOLS

LEARNING

CULTURE

AI · 18 November 2026

Isomorphic Labs Raises $5 Billion in Second Mega-Round in Six Months

Alphabet-owned Isomorphic Labs has raised $5 billion, its second mega-round in roughly six months after a $2.1 billion raise, according to reporting by The Decoder. The funds are intended to move its drug pipeline closer to clinical trials.

Newsdesk
Curated briefing · 2 min read

What happened

Isomorphic Labs, the AI drug discovery company owned by Alphabet and led by Demis Hassabis, has raised $5 billion in a new funding round. It is the company's second mega-round in roughly six months, following a $2.1 billion raise earlier in the period, according to reporting by The Decoder.

The company intends to use the capital to move its drug pipeline closer to clinical trials. Isomorphic Labs has not yet brought a drug to market, and none of its candidates is approved. The funding therefore signals a shift in emphasis from computational discovery toward the far more expensive work of testing candidates in people.

Why it matters

The round shows how quickly investor appetite for AI-led scientific discovery has grown. Capital at this scale is usually reserved for businesses with established revenue, yet Isomorphic Labs is raising it on the strength of its technology and pipeline rather than approved products. For leaders in AI and digital transformation, this is a signal that AI capability is being treated as core infrastructure for research-intensive sectors, not as a peripheral experiment.

The operational challenge also changes at this stage. Moving from in-silico design to clinical development brings trial design, regulatory engagement, data governance and patient recruitment into play. Those are service and experience problems as much as scientific ones, because the people involved in trials, from participants to clinicians, experience the process directly. Organisations applying AI to their own services face a similar test: the technology can accelerate the front end, but the experience of the people who depend on the outcome still has to be designed deliberately.

By the numbers

  • $5 billion: the size of Isomorphic Labs' latest funding round.
  • $2.1 billion: the size of the earlier round that preceded it.
  • Six months: the interval between the two mega-rounds.

The Renascence take

Most coverage will focus on the size of the cheque. The more useful question is what happens when an AI-native business has to prove itself to patients, regulators and clinicians rather than to investors and benchmarks. The principle underneath is that experience is decided at the point where a promise meets real human constraints, and in drug development those constraints are slow, costly and deeply personal.

Capital can buy speed in the lab, but it cannot buy trust in the clinic. Operators in any sector should treat the moment their AI moves from prediction to consequence as a service-design problem, not just a scaling problem. Map the human journeys that the technology will touch before the money arrives, not after. The companies that win will be the ones that design for the people on the other end of the output.

Sources

This briefing was written by our Newsdesk, synthesising reporting from the outlets below. Follow the links for the original coverage.

FAQ

Questions we get on this topic

Isomorphic Labs has raised $5 billion in a new funding round, according to reporting by The Decoder. It follows an earlier raise of $2.1 billion within roughly six months.

The company intends to use the capital to move its drug pipeline closer to clinical trials. It has not yet brought a drug to market, and none of its candidates is approved.

Isomorphic Labs is an AI drug discovery company owned by Alphabet and led by Demis Hassabis.

Stay ahead of CX

Get the signal, not the noise.

The stories shaping customer experience — plus the Journal and Experience Loom — in your inbox.